Jonker, D J <br/><br/>
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.  [electronic resource] 

 -  British journal of cancer  Feb 2014 
 - 648-55 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2013.753  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Cetuximab<br/>Clinical Trials, Phase III as Topic<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Epidermal Growth Factor--biosynthesis<br/>Epiregulin<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation<br/>Neoplasm Staging<br/>ras Proteins--genetics